| Year |
Citation |
Score |
| 2023 |
Tsipotis E, Maremanda A, Zeiser LB, Connolly C, Sharma S, Dudley-Brown S, Frey S, Lazarev M, Melia JM, Parian AM, Segev DL, Truta B, Yu H, Werbel WA, Selaru FM. Antibody Kinetics after Three Doses of SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease. Medicina (Kaunas, Lithuania). 59. PMID 37629777 DOI: 10.3390/medicina59081487 |
0.307 |
|
| 2023 |
Hughes RM, Frey S, Teles M, Connolly CM, Segev DL, Werbel WA, Chen PH. Durability of Antibody Response Six Months After Two-Dose SARS-CoV-2 mRNA Vaccination in Patients with Cirrhosis. Gastro Hep Advances. PMID 37360678 DOI: 10.1016/j.gastha.2023.03.025 |
0.324 |
|
| 2022 |
Teles MS, Connolly CM, Wallwork R, Frey S, Chiang TP, Alejo JL, Albayda J, Christopher-Stine L, Segev DL, Werbel WA, Paik JJ. Safety and immunogenicity of fifth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Rheumatology (Oxford, England). PMID 35758603 DOI: 10.1093/rheumatology/keac370 |
0.313 |
|
| 2022 |
Connolly CM, Frey S, Chiang TP, Teles M, Alejo JL, Albayda J, Shah AA, Werbel WA, Segev DL, Christopher-Stine L, Paik JJ. Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease. Rheumatology (Oxford, England). PMID 35583259 DOI: 10.1093/rheumatology/keac298 |
0.315 |
|
| 2022 |
Connolly CM, Chiang TP, Teles M, Frey S, Alejo JL, Massie A, Shah AA, Albayda J, Christopher-Stine L, Werbel WA, Segev DL, Paik JJ. Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases. The Lancet. Rheumatology. PMID 35368386 DOI: 10.1016/S2665-9913(22)00065-0 |
0.325 |
|
| 2022 |
Tsipotis E, Frey S, Connolly C, Werbel WA, Chowdhury R, Dudley-Brown S, Melia JM, Parian AM, Truta B, Yu H, Selaru FM, Segev DL, Lazarev M. Antibody Response Three Months after Two-Dose SARS-CoV-2 mRNA Vaccination in patients with Inflammatory Bowel Disease. The American Journal of Gastroenterology. PMID 35103023 DOI: 10.14309/ajg.0000000000001668 |
0.32 |
|
| 2022 |
Frey S, Chiang TP, Connolly CM, Teles M, Alejo JL, Boyarsky BJ, Christopher-Stine L, Werbel WA, Massie AB, Segev DL, Paik JJ. Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. The Lancet. Rheumatology. PMID 35072108 DOI: 10.1016/S2665-9913(21)00417-3 |
0.315 |
|
| 2022 |
Teles M, Connolly CM, Frey S, Chiang TP, Alejo JJ, Boyarsky BJ, Shah AA, Albayda J, Christopher-Stine L, Werbel WA, Segev DL, Paik JJ. Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Annals of the Rheumatic Diseases. PMID 35039324 DOI: 10.1136/annrheumdis-2021-221641 |
0.317 |
|
| 2021 |
Frey S, Connolly CM, Chiang TP, Teles M, Alejo JL, Boyarsky BJ, Christopher-Stine L, Werbel WA, Segev DL, Paik JJ. Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination. The Lancet. Rheumatology. 3: e753-e754. PMID 34725649 DOI: 10.1016/S2665-9913(21)00282-4 |
0.313 |
|
| 2021 |
Connolly CM, Teles M, Frey S, Boyarsky BJ, Alejo JL, Werbel WA, Albayda J, Christopher-Stine L, Garonzik-Wang J, Segev DL, Paik JJ. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Annals of the Rheumatic Diseases. PMID 34493492 DOI: 10.1136/annrheumdis-2021-221206 |
0.313 |
|
| 2015 |
Mbawuike IN, Atmar RL, Patel SM, Corry DB, Winokur PL, Brady RC, Chen WH, Edwards KM, Creech CB, Walter EB, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA. Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. PMID 26657997 DOI: 10.1016/j.vaccine.2015.11.055 |
0.362 |
|
| 2015 |
Troy JD, Hill HR, Ewell MG, Frey SE. Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE(®) smallpox vaccine. Vaccine. 33: 5425-31. PMID 26319063 DOI: 10.1016/J.Vaccine.2015.08.032 |
0.366 |
|
| 2015 |
Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Jama. 314: 237-46. PMID 26197184 DOI: 10.1001/jama.2015.7916 |
0.337 |
|
| 2015 |
George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, Frey SE, Huang CY, Stinchcomb DT. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. The Journal of Infectious Diseases. PMID 25791116 DOI: 10.1093/infdis/jiv179 |
0.321 |
|
| 2015 |
Petersen BW, Damon IK, Pertowski CA, Meaney-Delman D, Guarnizo JT, Beigi RH, Edwards KM, Fisher MC, Frey SE, Lynfield R, Willoughby RE. Clinical guidance for smallpox vaccine use in a postevent vaccination program. Mmwr. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports / Centers For Disease Control. 64: 1-26. PMID 25695372 |
0.398 |
|
| 2015 |
Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, et al. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 33: 163-73. PMID 25444805 DOI: 10.1016/J.Vaccine.2014.10.083 |
0.348 |
|
| 2014 |
Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, et al. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. Jama. 312: 1420-8. PMID 25291578 DOI: 10.1001/Jama.2014.12609 |
0.36 |
|
| 2014 |
Frey SE. New smallpox vaccines for an ancient scourge. Missouri Medicine. 111: 332-6. PMID 25211864 |
0.354 |
|
| 2014 |
Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 32: 5027-34. PMID 25045825 DOI: 10.1016/j.vaccine.2014.07.013 |
0.338 |
|
| 2014 |
Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, Goodwin R, Borkowski A, Clemens R, Mendelman PM. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. The Journal of Infectious Diseases. 210: 1763-71. PMID 24951828 DOI: 10.1093/infdis/jiu337 |
0.304 |
|
| 2014 |
Durviaux S, Treanor J, Beran J, Duval X, Esen M, Feldman G, Frey SE, Launay O, Leroux-Roels G, McElhaney JE, Nowakowski A, Ruiz-Palacios GM, van Essen GA, Oostvogels L, Devaster JM, et al. Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial. Clinical and Vaccine Immunology : Cvi. 21: 271-9. PMID 24371255 DOI: 10.1128/CVI.00544-13 |
0.303 |
|
| 2013 |
Frey SE, Lottenbach KR, Hill H, Blevins TP, Yu Y, Zhang Y, Brenneman KE, Kelly-Aehle SM, McDonald C, Jansen A, Curtiss R. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine. 31: 4874-80. PMID 23916987 DOI: 10.1016/J.Vaccine.2013.07.049 |
0.356 |
|
| 2013 |
Frey SE, Winokur PL, Salata RA, El-Kamary SS, Turley CB, Walter EB, Hay CM, Newman FK, Hill HR, Zhang Y, Chaplin P, Tary-Lehmann M, Belshe RB. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. Vaccine. 31: 3025-33. PMID 23664987 DOI: 10.1016/J.Vaccine.2013.04.050 |
0.353 |
|
| 2013 |
McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, ... Frey SE, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. The Lancet. Infectious Diseases. 13: 485-96. PMID 23518156 DOI: 10.1016/S1473-3099(13)70046-X |
0.33 |
|
| 2012 |
Frey SE, Bernstein DI, Gerber MA, Keyserling HL, Munoz FM, Winokur PL, Turley CB, Rupp RE, Hill H, Wolff M, Noah DL, Ross AC, Cress G, Belshe RB. Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. The Journal of Infectious Diseases. 206: 828-37. PMID 22802432 DOI: 10.1093/infdis/jis445 |
0.366 |
|
| 2012 |
Hughes CM, Newman FK, Davidson WB, Olson VA, Smith SK, Holman RC, Yan L, Frey SE, Belshe RB, Karem KL, Damon IK. Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines. Clinical and Vaccine Immunology : Cvi. 19: 1116-8. PMID 22593237 DOI: 10.1128/CVI.00056-12 |
0.383 |
|
| 2011 |
Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg RN. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. The Journal of Infectious Diseases. 204: 1395-402. PMID 21921208 DOI: 10.1093/infdis/jir527 |
0.352 |
|
| 2011 |
Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. The Journal of Infectious Diseases. 203: 1165-73. PMID 21451004 DOI: 10.1093/Infdis/Jiq175 |
0.332 |
|
| 2011 |
Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, ... Frey SE, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. The Journal of Infectious Diseases. 203: 610-9. PMID 21282192 DOI: 10.1093/Infdis/Jiq105 |
0.367 |
|
| 2011 |
Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, Martin W, De Groot AS. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine. 29: 501-11. PMID 21055490 DOI: 10.1016/J.Vaccine.2010.10.064 |
0.341 |
|
| 2010 |
Medina RA, Manicassamy B, Stertz S, Seibert CW, Hai R, Belshe RB, Frey SE, Basler CF, Palese P, García-Sastre A. Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nature Communications. 1: 28. PMID 20975689 DOI: 10.1038/Ncomms1026 |
0.324 |
|
| 2009 |
Handley L, Buller RM, Frey SE, Bellone C, Parker S. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Review of Vaccines. 8: 841-50. PMID 19538111 DOI: 10.1586/Erv.09.55 |
0.396 |
|
| 2009 |
Damon IK, Davidson WB, Hughes CM, Olson VA, Smith SK, Holman RC, Frey SE, Newman F, Belshe RB, Yan L, Karem K. Evaluation of smallpox vaccines using variola neutralization. The Journal of General Virology. 90: 1962-6. PMID 19339477 DOI: 10.1099/vir.0.010553-0 |
0.396 |
|
| 2009 |
Sano J, Chaitman BR, Swindle J, Frey SE. Electrocardiography Screening for Cardiotoxicity after Modified Vaccinia Ankara Vaccination American Journal of Medicine. 122: 79-84. PMID 19114175 DOI: 10.1016/J.Amjmed.2008.07.025 |
0.334 |
|
| 2009 |
Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, Monath TP. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine. 27: 1637-44. PMID 19071184 DOI: 10.1016/J.Vaccine.2008.11.079 |
0.351 |
|
| 2009 |
Monath TP, Frey SE. Possible autoimmune reactions following smallpox vaccination: The biologic false positive test for syphilis Vaccine. 27: 1645-1650. PMID 19022322 DOI: 10.1016/j.vaccine.2008.10.084 |
0.328 |
|
| 2009 |
Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine. 27: 243-9. PMID 18996425 DOI: 10.1016/J.Vaccine.2008.10.051 |
0.362 |
|
| 2009 |
Moise L, Ardito M, Desrosiers J, Schriewer J, Buller M, Frey SE, Gregory SH, Moss SF, Lee J, Kornfeld H, Martin B, De Groot AS. Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice Procedia in Vaccinology. 1: 15-22. DOI: 10.1016/J.Provac.2009.07.004 |
0.382 |
|
| 2007 |
Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine. 25: 6755-63. PMID 17692438 DOI: 10.1016/j.vaccine.2007.06.066 |
0.399 |
|
| 2007 |
Lawrence SJ, Lottenbach KR, Newman FK, Buller RM, Bellone CJ, Chen JJ, Cohen GH, Eisenberg RJ, Belshe RB, Stanley SL, Frey SE. Antibody responses to vaccinia membrane proteins after smallpox vaccination. The Journal of Infectious Diseases. 196: 220-9. PMID 17570109 DOI: 10.1086/518793 |
0.343 |
|
| 2007 |
Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. Journal of Acquired Immune Deficiency Syndromes (1999). 44: 203-12. PMID 17106277 DOI: 10.1097/01.Qai.0000248356.48501.Ff |
0.344 |
|
| 2004 |
Belshe RB, Newman FK, Frey SE, Couch RB, Treanor JJ, Tacket CO, Yan L. Dose-dependent neutralizing-antibody responses to vaccinia. The Journal of Infectious Diseases. 189: 493-7. PMID 14745707 DOI: 10.1086/380906 |
0.404 |
|
| 2004 |
De Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, Burke D, Evans TG, Corey L, Keefer MC. Safety profile of recombinant canarypox HIV vaccines Vaccine. 22: 704-713. PMID 14741163 DOI: 10.1016/J.Vaccine.2003.08.023 |
0.39 |
|
| 2003 |
Newman FK, Frey SE, Blevins TP, Mandava M, Bonifacio A, Yan L, Belshe RB. Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. Journal of Clinical Microbiology. 41: 3154-7. PMID 12843056 DOI: 10.1128/JCM.41.7.3154-3157.2003 |
0.378 |
|
| 2003 |
Frey SE, Newman FK, Yan L, Lottenbach KR, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. Jama. 289: 3295-9. PMID 12824212 DOI: 10.1001/jama.289.24.3295 |
0.329 |
|
| 2003 |
Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials Vaccine. 21: 2933-2947. PMID 12798637 DOI: 10.1016/S0264-410X(03)00158-0 |
0.397 |
|
| 2003 |
Newman FK, Frey SE, Blevins TP, Yan L, Belshe RB. Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax. The Journal of Infectious Diseases. 187: 1319-22. PMID 12696013 DOI: 10.1086/374564 |
0.351 |
|
| 2003 |
Frey SE. Unique risks to volunteers in HIV vaccine trials Journal of Investigative Medicine : the Official Publication of the American Federation For Clinical Research. 51: S18-20. PMID 12664950 |
0.318 |
|
| 2002 |
Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, Atmar RL, Edelman R, Nolan CM, Belshe RB. Clinical responses to undiluted and diluted smallpox vaccine. The New England Journal of Medicine. 346: 1265-74. PMID 11923490 DOI: 10.1056/NEJMoa020534 |
0.385 |
|
| 2002 |
Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polach T, Rothman AL, Kennedy JS, Wolff M, Belshe RB, Ennis FA. Dose-related effects of smallpox vaccine. The New England Journal of Medicine. 346: 1275-80. PMID 11923489 DOI: 10.1056/NEJMoa013431 |
0.346 |
|
| 2002 |
Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. Journal of Acquired Immune Deficiency Syndromes (1999). 29: 254-61. PMID 11873074 |
0.35 |
|
| 2001 |
Frey SE, Bollen W, Sizemore D, Campbell M, Curtiss R. Bacteremia associated with live attenuated χ8110 Salmonella enterica serovar typhi ISP1820 in healthy adult volunteers Clinical Immunology. 101: 32-37. PMID 11580224 DOI: 10.1006/Clim.2001.5088 |
0.359 |
|
| 1999 |
Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi S, Burke RL, Duliège AM. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine Journal of Infectious Diseases. 180: 1700-1703. PMID 10515836 DOI: 10.1086/315060 |
0.334 |
|
| 1999 |
Frey SE. HIV vaccines Infectious Disease Clinics of North America. 13: 95-112. PMID 10198794 DOI: 10.1016/S0891-5520(05)70045-3 |
0.364 |
|
| 1998 |
Gorse GJ, McElrath MJ, Matthews TJ, Hsieh RH, Belshe RB, Corey L, Frey SE, Kennedy DJ, Walker MC, Eibl MM. Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Vaccine. 16: 493-506. PMID 9491504 DOI: 10.1016/S0264-410X(97)80003-5 |
0.351 |
|
| 1996 |
Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. The Journal of Infectious Diseases. 173: 330-9. PMID 8568293 |
0.385 |
|
| 1995 |
Gorse GJ, Rogers JH, Perry JE, Newman FD, Frey SE, Patel GB, Belshe RB, the NIAID AIDS Vaccine Clinical Trials Network. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva Vaccine. 13: 209-214. PMID 7625118 DOI: 10.1016/0264-410X(95)93138-Y |
0.376 |
|
| 1994 |
Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB, NIAID AIDS Vaccine Clinical Trials Network. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins Vaccine. 12: 912-918. PMID 7975833 DOI: 10.1016/0264-410X(94)90034-5 |
0.333 |
|
| 1994 |
Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Frey SE, Belshe RB, Clements ML, Wright PF, Eibl M. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. Clinical and Experimental Immunology. 98: 178-84. PMID 7955519 DOI: 10.1111/J.1365-2249.1994.Tb06122.X |
0.37 |
|
| 1992 |
Gorse GJ, Belshe RB, Newman FK, Frey SE, NIAID AIDS Vaccine Clinical Trials Network. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160 Vaccine. 10: 383-388. PMID 1534641 DOI: 10.1016/0264-410X(92)90068-U |
0.338 |
|
| Show low-probability matches. |